back to US directory
us clinical guidance

Finerenone for CKD associated with type 2 diabetes

US FDA-label and guideline positioning, eligibility checks, potassium monitoring, interactions and cardiorenal follow-up for finerenone.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with chronic kidney disease associated with type 2 diabetes being considered for finerenone. This is an FDA-label and guideline-context page, not a replacement for comprehensive diabetes, blood-pressure, SGLT2-inhibitor, heart-failure or nephrology care.
sources for this section:FDA Kerendia labelADA Standards 2026KDIGO CKD 2024

The Bottom Line

  • The current US Kerendia label includes adults with CKD associated with type 2 diabetes to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction and hospitalization for heart failure.
  • Position finerenone as an added cardiorenal-risk treatment in an eligible patient with persistent albuminuric risk despite foundational care, not as a substitute for renin-angiotensin-system blockade or an indicated SGLT2 inhibitor.
  • Measure serum potassium and eGFR before initiation, choose the starting dose from current labeling, and do not initiate when potassium exceeds the label threshold.
  • Recheck potassium four weeks after starting, restarting or changing dose and periodically thereafter; withhold, restart or adjust only using the current label and the patient’s trend.
  • Review the full medication list because strong CYP3A4 inhibitors are contraindicated and other potassium-raising agents or CYP3A modifiers can materially alter risk or exposure.
sources for this section:FDA Kerendia labelADA Standards 2026KDIGO CKD 2024

Practical clinical workflow

1
Confirm type 2 diabetes, chronic albuminuric kidney disease, stable eGFR and current kidney-protective therapy; exclude an acute kidney injury or an alternative dominant kidney diagnosis.
2
Check potassium, eGFR, blood pressure, volume status, pregnancy potential where relevant, adrenal history, interacting drugs and the likelihood of reliable laboratory follow-up.
3
Select the labeled dose and provide counseling about hyperkalemia, acute illness, over-the-counter potassium or salt substitutes and the planned laboratory date.
4
Review potassium and eGFR at four weeks, then at an interval reflecting renal function, potassium trend, comedication and intercurrent illness; document every hold and restart decision.
5
Continue surveillance of albuminuria, diabetes, blood pressure and cardiovascular status and reassess net benefit when recurrent hyperkalemia or kidney-function instability prevents safe dosing.
sources for this section:FDA Kerendia labelADA Standards 2026

Safety boundaries and escalation

  • Do not use finerenone with a strong CYP3A4 inhibitor or in adrenal insufficiency; verify the current label because contraindications and interaction lists can change.
  • Hyperkalemia risk rises with lower kidney function and other potassium-raising therapy; weakness, palpitations or a markedly abnormal result requires prompt clinical assessment.
  • Use during pregnancy may cause fetal harm according to labeling; address reproductive counseling and lactation with the current prescribing information.
  • A sudden eGFR decline, dehydration, sepsis or another acute illness should trigger clinical review rather than automatic continuation or permanent discontinuation.
sources for this section:FDA Kerendia label

Localization

Insurer authorization may require documentation of albuminuria and foundational therapy, but administrative denial is not clinical evidence. Use the current US label for dose and interaction decisions.
sources for this section:FDA Kerendia labelADA Standards 2026KDIGO CKD 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Food and Drug AdministrationKERENDIA (finerenone) tablets, current US prescribing informationDrugs@FDA application 215341; current label checked 2026-08-20 · accessed 2026-08-20
    view source
  2. American Diabetes Association Professional Practice Committee for DiabetesStandards of Care in Diabetes—20262026 Standards of Care, including living online updates · published 2025-12-08 · accessed 2026-08-20
    view source
  3. Kidney Disease: Improving Global OutcomesKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseDOI 10.1016/j.kint.2023.10.018 · published 2024-03-13 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.